HK Stock Market Move | QYUNS-B (02509) rose nearly 9% as the application for the listing of Lusetchituximab (QX002N) was accepted.

QYUNS-B (02509) rose nearly 9%, closing at an increase of 8.92% to HK$18.19, with a turnover of HK$1.2474 million. On the news front, Quanxin Biotechnology announced that the new drug application (NDA) for the company's first innovative drug "Rusichitadumab monoclonal antibody (QX002N)" has been accepted by the National Medical Products Administration (acceptance number: CXSS2600039), for the treatment of adult ankylosing spondylitis (AS). Rusichitadumab monoclonal antibody is the company's first innovative drug to receive NDA acceptance, and the second biologic drug to reach the NDA stage after Secukinumab, marking the company's research and development pipeline gradually entering the harvest period. Industrial research reports previously stated that Quanxin Biotechnology is a biotechnology company focused on biologics therapy for autoimmune and allergic diseases, with a rich self-developed pipeline and mature commercial production capabilities. The company's main pipeline is in the commercialized or late-stage clinical stage, with strong potential.